Digital Phenotyping and Digital Biomarkers Market Size to Grow At 10.4% CAGR From 2024 to 2030.

Global Digital Phenotyping and Digital Biomarkers Market Size (2024 – 2030)

As per our research report, the Digital Phenotyping and Digital Biomarkers Market size is estimated to be growing at a CAGR of 10.4% from 2024 to 2030.

Biomarkers serve as objective indicators reflecting an individual's anatomical, physiological, and pathological traits to assess health status and detect bodily warning signs. Digital biomarkers, on the other hand, are quantifiable behavioral and physiological data obtained and assessed through digital devices, including portable, wearable, and implantable technologies. These digital biomarkers provide substantial imaging capabilities with improved spatial resolution.

Digital phenotyping involves extracting information from data streams and digital devices to perform personalized real-time analysis, providing accurate data. This process can identify traits and patterns within a population by utilizing their active or passive data, effectively devising treatment strategies for mental disorders. Neurological and psychiatric diseases exhibit complex, fluctuating, and atypical symptoms with high variability among patients. Traditional diagnostic and efficacy evaluation methods often rely on in-clinic visits and subjective assessments by caregivers, clinicians, and patients, which are often time-consuming, costly, and limited in quality and quantity of observations.

Digital biomarkers enable frequent assessments of a larger target population over extended periods. The increased use of smart wearables and connected devices facilitates the measurement of various diagnostic parameters for diseases such as diabetes, mental health disorders, cardiovascular conditions, and neurological diseases. The rise of smartwatches and the widespread usage of smartphones assist in tracking health-related physiological data.

The advent of connected devices like smart wearables, portable devices, and biosensors has greatly enhanced the ability to measure various parameters for detecting novel biomarkers. Mobile health apps include various physiological parameters such as sleep, activity, and heart rate, alongside biochemical parameters like metabolites, electrolytes, proteins, and small molecules. These advancements offer significant opportunities to revolutionize data capture and collection processes during clinical trials. The increasing use of connected devices and health-related mobile applications supports diagnostic and prognostic measurements of various diseases, thereby driving market growth for digital phenotyping and digital biomarkers. The growing use of mobile devices generates vast amounts of personalized data, including location, physical movement, vital health signs, and social media habits, which can be processed through data mining.

The global digital phenotyping and digital biomarkers market is dominated by numerous digital health companies, categorized as developers of sensors and tools that collect and integrate patient-level data. Prominent players in this market are engaged in synergistic activities, innovative product launches, acquisitions, collaborations with research and medical institutions, business expansion, and funding activities to enhance the digital phenotyping and digital biomarker space.


  • Based on the Component, the Data Collection Tools segment held a significant revenue share in the global market and is expected to maintain its dominance throughout the forecast period. This is due to the increased adoption of smartphones and wearables, which greatly aid in data collection. The Internet and wireless connectivity are key tools that facilitate easy data collection and transfer. Biosensors account for a major portion of data collection tools. The Data Integration Systems segment is projected to grow during the forecast period.
  • Based on the Application, the cardiovascular diseases segment leads the global market in terms of revenue and is expected to maintain its dominance throughout the forecast period. This is due to the increased global prevalence of cardiovascular diseases. According to WHO, cardiovascular diseases are responsible for 32% of global deaths. The Respiratory Conditions segment is projected to be the fastest-growing segment during the forecast period, driven by the rising prevalence of respiratory diseases such as chronic obstructive pulmonary disease and asthma.
  • Based on the End-User, the Biopharmaceutical Companies & Labs segment currently dominates the market share and is expected to hold the largest revenue during the forecast period. The Insurance Payers segment is projected to grow at the highest rate, approximately 43%, during the forecast period.
  • Based on the region, the North American Digital Phenotyping and Digital Biomarkers Market holds the largest market share and is expected to account for a significant revenue share globally during the forecast period. Key factors contributing to this growth include a large geriatric population, significant product launches, a higher adoption rate of digital technologies, increased investments in research and development, rising healthcare expenditure, growing approval of smart devices in the region, and a strong presence of key market players. Latin America, the Middle East, and Africa are anticipated to experience growth during the forecast period due to increasing cases of chronic diseases, a growing need to manage healthcare costs, and the increasing use of smartphones and the internet.
  • Companies playing a leading role in the Digital Phenotyping and Digital Biomarkers market profiled in this report are Akili Interactive Labs, ActiGraph, LLC., Novartis, Fitbit, Inc., AliveCor, Inc., Sanofi, Pfizer Inc.

Global Digital Phenotyping and Digital Biomarkers Market Segmentation:

By Component:

  • Data Collection Tools
  • Digital Platforms
  • Mobile Apps
  • Desktop-based Software
  • Wearables
  • Biosensors
  • Data Integration Systems

By Application:

  • Sleep and Movement
  • Mood and Behavior
  • Neurodegenerative Disorders
  • Cardiological Diseases
  • Diabetes
  • Chronic pain
  • Respiratory Conditions
  • Gastrointestinal Diseases
  • Others

By End User:

  • Biopharmaceutical Companies & labs
  • Insurance Payers
  • Healthcare Providers

By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Request Sample Copy Of This Report @

Analyst Support

Every order comes with Analyst Support.


We offer customization to cater your needs to fullest.

Verified Analysis

We value integrity, quality and authenticity the most.